Zobrazeno 1 - 10
of 112
pro vyhledávání: '"Witold Tomkowski"'
Autor:
Malgorzata Sobiecka, Izabela Siemion-Szczesniak, Barbara Burakowska, Marcin Kurzyna, Malgorzata Dybowska, Witold Tomkowski, Monika Szturmowicz
Publikováno v:
BMC Pulmonary Medicine, Vol 24, Iss 1, Pp 1-9 (2024)
Abstract Background Sarcoidosis-associated pulmonary hypertension (SAPH) is listed in Group 5 of the clinical classification of pulmonary hypertension, due to its complex and multifactorial pathophysiology. The most common cause of SAPH development i
Externí odkaz:
https://doaj.org/article/2cbe810ad3814d2296d566be2c269baf
Autor:
Małgorzata Dybowska, Dariusz Dybowski, Monika Szturmowicz, Adam Jóźwik, Katarzyna Lewandowska, Małgorzata Sobiecka, Witold Tomkowski
Publikováno v:
Cancer Control, Vol 30 (2023)
Background The importance of D-dimers (DD) assessment in the diagnostic algorithm of venous thromboembolic (VTE) disease is well known. Increase of DD concentration may be also associated with neoplastic disease. Many studies documented that high con
Externí odkaz:
https://doaj.org/article/8cdd62dd4a8547609ec96c5cd1df605e
Publikováno v:
Diagnostics, Vol 13, Iss 19, p 3132 (2023)
Sarcoidosis has been a well-recognised risk factor for pulmonary hypertension (PH) for a long time, but still, the knowledge about this concatenation is incomplete. Sarcoidosis-associated PH (SAPH) is an uncommon but serious complication associated w
Externí odkaz:
https://doaj.org/article/80897cfef1124e91b063089f1378c05a
Autor:
Małgorzata Sobiecka, Monika Szturmowicz, Katarzyna Lewandowska, Agata Kowalik, Ewa Łyżwa, Katarzyna Zimna, Inga Barańska, Lilia Jakubowska, Jan Kuś, Renata Langfort, Witold Tomkowski
Publikováno v:
BMC Pulmonary Medicine, Vol 21, Iss 1, Pp 1-12 (2021)
Abstract Background Idiopathic pulmonary fibrosis (IPF) and chronic hypersensitivity pneumonitis share commonalities in pathogenesis shifting haemostasis balance towards the procoagulant and antifibrinolytic activity. Several studies have suggested a
Externí odkaz:
https://doaj.org/article/73201d28f8c5448d9ae3c51e5159f78d
Publikováno v:
Diagnostics, Vol 13, Iss 14, p 2354 (2023)
The prevalence of pulmonary hypertension (PH) complicating interstitial lung diseases (ILDs) is 3.5–15% at an early stage, and up to 90% in ILD patients listed for lung transplantation. In addition, other types of PH may occur in patients with ILDs
Externí odkaz:
https://doaj.org/article/7f4ab07c06784c898e0ca7b571d309e4
Autor:
Katarzyna Błasińska, Małgorzata Ewa Jędrych, Lucyna Opoka, Witold Tomkowski, Monika Szturmowicz
Publikováno v:
Biomedicines, Vol 11, Iss 7, p 1866 (2023)
Sarcoidosis is a multisystem granulomatous disease of unknown origin. The most frequent localizations are thoracic lymph nodes and/or parenchymal lung disease, nevertheless any other organ may be involved. Musculoskeletal sarcoidosis, previously cons
Externí odkaz:
https://doaj.org/article/903a1f927fed4402b203f5e7462042ac
Autor:
Katarzyna Górska, Marta Maskey-Warzęchowska, Małgorzata Barnaś, Adam Białas, Adam Barczyk, Hanna Jagielska-Len, Ewa Jassem, Aleksander Kania, Katarzyna Lewandowska, Sebastian Majewski, Magdalena M. Martusewicz-Boros, Wojciech J. Piotrowski, Alicja Siemińska, Krzysztof Sładek, Małgorzata Sobiecka, Marzena Trzaska-Sobczak, Witold Tomkowski, Beata Żołnowska, Rafał Krenke
Publikováno v:
Therapeutic Advances in Chronic Disease, Vol 13 (2022)
Background: Pirfenidone and nintedanib are considered as the standard of care in idiopathic pulmonary fibrosis (IPF), but there is no consensus as to which of these two agents should be regarded as first-line treatment. Objective: To provide real-wor
Externí odkaz:
https://doaj.org/article/f292078d43f34b2ea0136d89cf7f4dc6
Publikováno v:
BMC Cardiovascular Disorders, Vol 20, Iss 1, Pp 1-6 (2020)
Abstract Background Pericardial constriction is one of the complications of purulent pericarditis (PP). Most difficult to treat, which may develop both in early and in the late period of the disease, resulting in a very poor prognosis. Case presentat
Externí odkaz:
https://doaj.org/article/9ad8632ce0e54c7988a9cf320b32febd
Autor:
Sebastian Majewski, Adam J. Białas, Małgorzata Buchczyk, Paweł Gomółka, Katarzyna Górska, Hanna Jagielska-Len, Agnieszka Jarzemska, Ewa Jassem, Dariusz Jastrzębski, Aleksander Kania, Marek Koprowski, Rafał Krenke, Jan Kuś, Katarzyna Lewandowska, Magdalena M. Martusewicz-Boros, Kazimierz Roszkowski-Śliż, Alicja Siemińska, Krzysztof Sładek, Małgorzata Sobiecka, Karolina Szewczyk, Małgorzata Tomczak, Witold Tomkowski, Elżbieta Wiatr, Dariusz Ziora, Beata Żołnowska, Wojciech J. Piotrowski
Publikováno v:
BMC Pulmonary Medicine, Vol 20, Iss 1, Pp 1-12 (2020)
Abstract Background Pirfenidone is an antifibrotic agent approved for the treatment of idiopathic pulmonary fibrosis (IPF). The drug is available for Polish patients with IPF since 2017. The PolExPIR study aimed to describe the real-world data (RWD)
Externí odkaz:
https://doaj.org/article/819a0c653b2745e99c064475c66a7334
Autor:
Monika Szturmowicz, Barbara Garczewska, Małgorzata Jędrych, Iwona Bartoszuk, Małgorzata Sobiecka, Witold Tomkowski, Ewa Augustynowicz-Kopeć
Publikováno v:
Central European Journal of Immunology, Vol 44, Iss 4, Pp 390-394 (2020)
Externí odkaz:
https://doaj.org/article/95bca21ae73c43fe9ab606bcafc9a607